丙型肝炎肝硬化抗病毒治疗现状

张达利; 张敏; 苏海滨

丙型肝炎肝硬化抗病毒治疗现状

解放军第302医院移植内科

详细信息

中图分类号: R575.2
计量
- 文章访问数: 3116
- HTML全文浏览量: 18
- PDF下载量: 1298
- 被引次数: 0
出版历程
- 出版日期: 2012-09-20

Current perspectives on antiviral therapy for hepatitis C-related cirrhosis

摘要

摘要: 目前干扰素联合利巴韦林是慢性HCV感染的主要抗病毒治疗方案,但丙型肝炎肝硬化患者对于抗病毒治疗耐受性差。目前研究报道对于丙型肝炎肝硬化患者进行抗病毒治疗,如能获得持续病毒学应答(SVR),有利于缓解肝纤维化进展,并减少肝移植术后HCV再感染的发生。因此,应对丙型肝炎肝硬化患者进行仔细评估,对于进行抗病毒治疗的患者可给予适当干预以维持抗病毒治疗的进行,并在治疗过程中密切监测不良反应的发生。
- 肝炎,丙型,慢性 /
- 肝硬化 /
- 抗病毒药
Abstract: The most effective and widely used treatment for patients with chronic hepatitis C virus (HCV) infection is anti-viral therapy with a combination of interferon (IFN) and ribavirin.However, the tolerability for these drugs is low in patients with cirrhosis.Many studies have shown that HCV-related cirrhosis patients who achieve sustained viral response (SVR) after anti-viral therapy have significantly slower progression of liver fibrosis and a lower rate of HCV recurrence after liver transplantation.Therefore, patients with HCV-related cirrhosis should be monitored carefully to recognize and resolve adverse side effects of anti-viral treatments in a timely manner and to predict success of transplantation with non-recurrence.
- hepatitis C /
- chronic /
- liver cirrhosis

HTML全文

参考文献(24)

[1]戚中田.丙型肝炎病毒感染与治疗药物[J].临床肝胆病杂志, 2011, 27 (1) :15-18.

[2]Pizarro C, Venegas M, Hola K, et al.Results of treatmentwith peginterferon plus ribavirin in patients with chronic hepa-titis[J].Rev Med Chil, 2011, 139 (6) :704-709.

[3]Toyoda H, Kumada T.Incidence of hepatocellular carcinomaand response to interferon therapy in HCV-infected pa-tients:effect of factors associated with the therapeutic re-sponse and incidence of HCC[J].Liver Int, 2012, 32 (16) :1029-1031.

[4]Sherman KE.Advanced liver disease:what every hepatitis Cvirus treater should know[J].Top Antivir Med, 2011, 19 (3) :121-125.

[5]Rubín A, Aguilera V, Berenguer M.Liver transplantation andhepatitis C[J].Clin Res Hepatol Gastroenterol, 2011, 35 (12) :805-812.

[6]European Association for the Study of the Liver.EASL ClinicalPractice Guidelines:Management of hepatitis C virus infec-tion[J].J Hepatol, 2011, 55 (2) :245-264.

[7]Berger A.Antiviral treatment of chronic hepatitis C[J].MedMonatsschr Pharm, 2012, 35 (2) :55-60.

[8]Van Gulick JJ, Lamers MH, Drenth JP.Hepatitis C virus in-fection management in 2012[J].Panminerva Med, 2012, 54 (1) :1-9.

[9]Liu J, Shi S, Zhuang H, et al.Recent advance in antiviraldrugs for hepatitis C[J].Zhong Nan Da Xue Xue Bao Yi XueBan, 2011, 36 (11) :1025-1036.

[10]Fried MW, Shiffman ML, Reddy KR, et al.Peginterferon al-fa-2a plus ribavirin for chronic hepatitis C virus infection[J].N Engl J Med, 2002, 347 (13) :975-982.

[11]Tao J, Liu J, Pu D, et al.Efficacy of interferon alpha withribavirin for treatment of chronic Hepatitis C[J].ZhonghuaGan Zang Bing Za Zhi, 2011, 19 (9) :683-5.

[12]Yoshida H, Arakawa Y, Sata M, et al.Interferon therapyprolonged life expectancy among chronic hepatitis C patients[J].Gastroenterology, 2002, 123 (2) :483-491.

[13]Poynard T, McHutchison J, Manns M, et al.Impact of pe-gylated interferon alfa-2b and ribavirin on liver ibrosis in pa-tients with chronic hepatitis C[J].Gastroenterology, 2002, 122 (5) :1303-1313.

[14]Benvegnu L, Chemello L, Noventa F, et al.Retrospective a-nalysis of the effect of interferon therapy on the clinical out-come of patients with viral cirrhosis[J].Cancer, 1998, 83 (5) :901-909.

[15]Di Marco V, Almasio PL, Ferraro D, et al.Peg-interferon a-lone or combined with ribavirin in HCV cirrhosis with portalhypertension:a randomized controlled trial[J].J Hepatol, 2007, 47 (4) :484-491.

[16]Iacobellis A, Perri F, Valvano MR, et al.Long-term outcomeafter antiviral therapy of patients with hepatitis C virus infectionand decompensated cirrhosis[J].Clin Gastroenterol Hepatol, 2011, 9 (3) :249-253.

[17]Iacobellis A, Siciliano M, Perri F, et al.Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decom-pensated cirrhosis:a controlled study[J].J Hepatol, 2007, 46 (2) :206-212.

[18]Everson GT, Trotter J, Forman L, et al.Treatment of ad-vanced hepatitis C with a low accelerating dosage regimen ofantiviral therapy[J].Hepatology, 2005, 42 (2) :255-262.

[19]Crippin JS, McCashland T, Terrault N, et al.A pilot study ofthe tolerability and eficacy of antiviral therapy in hepatitis C vi-rus-infected patients awaiting liver transplantation[J].LiverTranspl, 2002, 8 (4) :350-355.

[20]Bacon BR, Khalid O.New therapies for hepatitis C virus in-fection[J].Mo Med, 2011, 108 (4) :255-259.

[21]Peck-Radosavljevic M, Wichlas M, Homoncik-kraml M, et al.Rapid suppression of hematopoiesis by standard or pe-gylated interferon-alpha[J].Gastroenterology, 2002, 123 (1) :141-151.

[22]Di Marco V, Almasio PL, Ferraro D, et al.Peg-interferon a-lone or combined with ribavirin in HCV cirrhosis with portalhypertension:a randomized controlled trial[J].J Hepatol, 2007, 47 (4) :484-491.

[23]Vezali E, Aghemo A, Colombo M.A review of the treatmentof chronic hepatitis C virus infection in cirrhosis[J].Clin T-her, 2010, 32 (13) :2117-2138.

[24]Van Gulick JJ, Lamers MH, Drenth JP.Hepatitis C virus in-fection management in 2012[J].Panminerva Med, 2012, 54 (1) :1-9.

施引文献

资源附件(0)

访问统计